1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed is sponsored by National Institutes of Health (NIH).
This funding opportunity invites small business concerns to submit Small Business Technology Transfer (STTR) Phase I and Phase II grant applications to support the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. It focuses on platforms associated with the production, manufacturing, and use of native or engineered EVs as therapeutics.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the opportunity page linked on this listing to help you evaluate fit faster.
NOT-TR-24-019: Notice of Change to Application Types Allowed in PAR-23-268 Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed Notice of Change to Application Types Allowed in PAR-23-268 Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed April 18, 2023 - Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2 Clinical Trials Not Allowed).
See NOFO PAR-23-268 . National Center for Advancing Translational Sciences ( NCATS ) The purpose of this Notice is to change the application types allowed in PAR-23-268, Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine, to include Renewal (Phase II) applications. Part 2.
Full Text of Announcement Section II. Award Information New (Phase I, Fast-Track) Resubmission (All Phases) Corrected to read (in bold italics): Resubmission (All Phases) New (Phase I, Fast-Track) All other aspects of the NOFO remain unchanged. Please direct all inquiries to: Office of Special Initiatives National Center for Advancing Translational Sciences (NCATS) Weekly TOC for this Announcement NIH...
Turning Discovery Into Health ®
According to the current listing, eligibility includes: Eligible United States small business concerns (SBCs). Confirm the full requirements in the official notice before applying.
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PAR-27-003 opens the NIGMS-style RM1 to 13 NIH institutes through September 2029: 3 to 6 PIs, up to $1.5M in direct costs a year but most awards $500K to $900K, at least 2.4 months of effort per PI, and a 20-page strategy with a mandatory Team Integration Plan. The NIGMS predecessor made 4 new awards in three years.
Read articleThe October 6, 2026 Director's Awards cohort is NIH's most expensive in four years at about $4.1 million per award. New Innovator rebounded from 29 to 42 while Early Independence fell from 13 to 3 after the program skipped its FY2026 competition. Here is what the composition shift means for FY2027 and FY2028 applicants.
Read articleOn October 7, 2026, Biohub, DOE, NIH, Google DeepMind, Isomorphic Labs and Meta committed $1.8 billion to build AI-ready biological data. More than $500 million of it is DOE money flowing through the Genesis Mission, and NIH's share is data rather than dollars. There is no NOFO — here is where the applyable money actually sits.
Read article